Guangzhou Kingmed Diagnostics Group Co Ltd

KingMed Diagnostics released its 2026 interim report, showing a net profit attributable to shareholders of 190 million yuan for the first half, swinging from a loss in the same period last year. Revenue was 2.88 billion yuan, down 3.8 percent year on year. Net profit attributable to shareholders excluding non-recurring items was 203 million yuan, compared with a loss of 97.96 million yuan a year earlier. Net operating cash flow was 243 million yuan, down 30.8 percent year on year. Second-quarter revenue was 1.53 billion yuan, up 0.2 percent year on year, with net profit attributable to shareholders of 147 million yuan. The company said that against the backdrop of healthcare reform, an ageing population and the development of county-level medical systems, the third-party medical testing industry is adjusting its pricing methods, service scenarios and capability structure. KingMed has set a medium- and long-term strategic goal of building a globally leading smart service platform for medical diagnostics.

KingMed Diagnostics announced that as of July 31, 2026, the company had repurchased 6.77 million shares, accounting for 1.46% of total share capital, with a total repurchase amount of 178 million yuan, at a price range of 23.36 yuan to 28.79 yuan per share. In the first quarter of 2026, the company achieved revenue of 1.351 billion yuan and net profit attributable to the parent company of 42.79 million yuan.